Recent studies have shown that SGLT2 inhibitors may inhibit activation of the NLRP3 inflammasome in several animal models, including obesity, lung injury, myocardial infarction, DKD, depression and atherosclerosis. This evidence concerns the gene SLC5A2 and atherosclerosis.